Columbus Macro LLC Boosts Stake in Johnson & Johnson $JNJ

Key Points

• Columbus Macro LLC increased its stake in Johnson & Johnson by 4.5% during the 2nd quarter, now holding 35,415 shares valued at approximately $5.41 million.
• Johnson & Johnson reported $2.26 earnings per share for the last quarter, with a net margin of 25% and a return on equity of 32.49%.
• The company announced a quarterly dividend of $1.30 per share, representing a 2.7% yield and a payout ratio of 55.61%.

Columbus Macro LLC lifted its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 4.5% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 35,415 shares of the company's stock after buying an additional 1,532 shares during the period. Columbus Macro LLC's holdings in Johnson & Johnson were worth $5,410,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently bought and sold shares of JNJ. Highline Wealth Partners LLC raised its stake in Johnson & Johnson by 51.8% during the first quarter. Highline Wealth Partners LLC now owns 252 shares of the company's stock worth $42,000 after purchasing an additional 86 shares during the period. Stone House Investment Management LLC purchased a new stake in shares of Johnson & Johnson in the 1st quarter valued at approximately $47,000. 1248 Management LLC purchased a new stake in shares of Johnson & Johnson in the 1st quarter valued at approximately $48,000. von Borstel & Associates Inc. purchased a new stake in shares of Johnson & Johnson in the 1st quarter valued at approximately $49,000. Finally, Harvest Fund Management Co. Ltd purchased a new stake in shares of Johnson & Johnson in the 1st quarter valued at approximately $52,000. 69.55% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the company's stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the transaction, the executive vice president owned 178,013 shares in the company, valued at approximately $31,652,491.53. This represents a 24.08% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 0.16% of the company's stock.

Johnson & Johnson Price Performance

Shares of JNJ opened at $190.66 on Friday. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $192.10. The firm's fifty day simple moving average is $178.48 and its 200-day simple moving average is $163.76. The firm has a market capitalization of $459.16 billion, a price-to-earnings ratio of 20.39, a PEG ratio of 2.40 and a beta of 0.40. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The business had revenue of $24.02 billion for the quarter. Equities analysts forecast that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th were issued a dividend of $1.30 per share. The ex-dividend date of this dividend was Tuesday, August 26th. This represents a $5.20 dividend on an annualized basis and a yield of 2.7%. Johnson & Johnson's dividend payout ratio (DPR) is presently 55.61%.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on JNJ. Wells Fargo & Company set a $212.00 price target on shares of Johnson & Johnson and gave the company an "overweight" rating in a research note on Friday, October 3rd. Bank of America boosted their price target on shares of Johnson & Johnson from $175.00 to $198.00 and gave the company a "neutral" rating in a research note on Friday, October 3rd. Wall Street Zen raised shares of Johnson & Johnson from a "hold" rating to a "buy" rating in a research note on Saturday, September 13th. UBS Group set a $198.00 target price on shares of Johnson & Johnson in a research note on Friday, October 3rd. Finally, The Goldman Sachs Group raised their price target on shares of Johnson & Johnson from $186.00 to $212.00 and gave the company a "buy" rating in a research report on Thursday. Two investment analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and eight have issued a Hold rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $192.94.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.